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Abstract
Objective: Probiotics and prebiotics that affect gut microflora balance and its associated enzymeactivity
may contribute to interindividual variation in isoflavone absorption after soy intake, possiblyenhancing
isoflavone bioavailability. This study examined the effects of the consumption ofbioactive yogurt (a
probiotic) or resistant starch (a known prebiotic) in combination with high soyintake on soy isoflavone
bioavailability.Methods: Using a crossover design, chronic soy consumption was compared with soy
plusprobiotic yogurt or resistant starch in older male and postmenopausal females (n 31).
Isoflavonebioavailability was assessed at the beginning and end of each 5-wk dietary period by
samplingplasma and urine after a standardized soy meal.Results: Chronic soy intake did not significantly
affect plasma or urinary isoflavones after the soymeal and there were no significant effects of probiotic or
resistant starch treatment. However, therewere trends for increased circulating plasma daidzein and
genistein after the probiotic treatment andfor increased plasma daidzein and genistein 24 h after soy
intake with resistant starch treatment.Neither treatment induced or increased equol production, although
there was a trend for increasedplasma equol in equol-positive subjects (n 12) after probiotic
treatment.Conclusion: The weak or absence of effects of probiotic yogurt or resistant starch supplement
toa chronic soy diet suggests that gut microflora were not modified in a manner that significantlyaffected
isoflavone bioavailability or metabolism.
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Abstract
Objective: Probiotics and prebiotics that affect gut microflora balance and its associated
enzyme activity may contribute to inter-individual variation in isoflavone absorption
following soy intake, possibly enhancing isoflavone bioavailability. This study examined
the effects of the consumption of a probiotic (bioactive yogurt) or a prebiotic (resistant
starch) in combination with high soy intake, on soy isoflavone bioavailability.
Research Methods and Procedures: Using a crossover design, chronic soy consumption
was compared with soy plus either probiotic or prebiotic foods in older male and
postmenopausal females (n = 31). Isoflavone bioavailability was assessed at the
beginning and end of each 5 week dietary period by sampling plasma and urine after a
standardized soy meal.
Results: Chronic soy intake did not significantly affect plasma or urinary isoflavones
following the soy meal and there were no significant effects of either probiotic or
prebiotic treatment. However, there were trends for increased circulating plasma
daidzein and genistein after the probiotic treatment and for increased plasma daidzein and
genistein 24 h post soy intake with the prebiotic treatment. Neither probiotic nor
prebiotic treatment induced or increased equol production, though there was a trend for
increased plasma equol in “equol-positive” subjects (n = 12) after probiotic treatment.
Conclusion: The weak or absence of effects of probiotic or prebiotic supplement to a
chronic soy diet suggests that gut microflora were not modified in a manner that
significantly affected isoflavone bioavailability or metabolism.
Key Words: isoflavone, probiotic, prebiotic, bioavailability, daidzein, genistein
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INTRODUCTION
Gut microflora plays an essential role in soy isoflavone absorption, metabolism and
bioavailability by virtue of its enzymatic activity (1-3). Differences in gut microfloral profiles
may contribute to the large inter-individual variation typical for isoflavone bioavailability
following soy intake. The enzymes most pertinent to isoflavone bioavailability are the βglucosidases, for initial glucoside hydrolysis and subsequent aglycone absorption, and the βglucuronidases and sulphatases, for reabsorption of the hepatic conjugates and biliary excretion
(4). The initial hydrolysis of soy isoflavone glucosides to their respective aglycones is suggested
to be the rate-limiting step in isoflavone absorption (5-7); thus, β-glucosidases activity may be
particularly important in relation to isoflavone bioavailability. Bacterial species of bacteroides,
bifidobacteria and lactobacilli have the highest activity of this enzyme (7-9).
Lactobacilli and bifidobacteria are unique in being exclusively beneficial to the host (10)
and thus are termed “probiotic bacteria” (11). Live cultures of these bacteria can be provided in
food matrices, such as fermented milk products, to introduce them to the gastrointestinal tract
(12) where they subsequently colonize the small intestine and colon (13). Alternatively, the
growth and/or activity of specific probiotic bacteria already resident in the gut can be selectively
stimulated by intake of prebiotic dietary components (14). Resistant starch is such a prebiotic; it
is fermented in the large bowel specifically by bifidobacteria (15) and consequently increases βglucosidase activity (16). By altering gut microflora balance and increasing β-glucosidase
activity, probiotic bacteria may also enhance isoflavone absorption. Furthermore, the metabolism
of daidzein to equol relies exclusively on intestinal bacteria (17) and this conversion may be
particularly important as equol has significantly enhanced antioxidant activity compared with
daidzein (18,19) and may increase potential health benefits (20). Thus, we hypothesized that
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intake of either probiotic cultures or a prebiotic dietary component may affect soy isoflavone
bioavailability, including equol production. A crossover study was conducted in which plasma
and urinary isoflavone levels after 5 weeks of daily intake of soy foods were compared with those
after 5 weeks of daily intake of soy in combination with either yogurt containing probiotic
bacteria or bread containing the prebiotic, resistant starch.

MATERIALS AND METHODS
Subjects
Male and female subjects, recruited via the local media, were required to be at least 45
years old and mildly hypercholesterolemic (total cholesterol greater than 5.5 mmol/L). A
secondary aim of this study was to determine the effects of soy in combination with a probiotic or
prebiotic on lipids (Larkin et al, manuscript submitted), hence the latter criterion. Further,
women had to be post-menopausal for more than 12 months and not taking hormone replacement
therapy (HRT) for the previous 6 months. Further exclusion criteria included the use of
cholesterol-lowering medication, antibiotics or probiotic-containing foods or supplements within
2 months prior to the study, an average alcohol intake of greater than 2 standard drinks per day
and cigarette smoking.
Study Design
The study consisted of 2 separate cohorts, both of randomized crossover design (Figure
1), with each subject acting as his or her own control. The probiotic cohort was double-blinded;
the prebiotic cohort was not blinded. After a two-week wash-in period during which soy foods,
yogurt, Hi-MaizeTM bread (high resistant starch content) and probiotic supplements were
excluded from the diet, subjects commenced the study, which involved two 5-week dietary
periods separated by a 4-week washout, which required the same dietary exclusions as the wash-
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in period. Subjects were instructed to otherwise maintain their normal diets for the duration of
the study so that other prebiotic dietary components would remain constant. This study design
enabled us to examine the effects of increased intake of probiotic yogurt or the prebiotic, resistant
starch. Subjects completed a dietary questionnaire during each of the wash-in and washout
periods and during both dietary periods.
All subjects consumed soy milk and soy cereal daily during both dietary periods; this diet
was further supplemented with either the probiotic or prebiotic foods for the corresponding
intervention. A test soy meal was consumed prior to and at the end of both 5-week dietary
periods for determination of subsequent isoflavone bioavailability. Subjects were allocated to
one of four groups (Pro-1, Pro-2, Pre-1 or Pre-2), which determined the intervention (probiotic or
prebiotic) and the order of crossover (Figure 1). The control and active dietary treatments for the
probiotic cohort were soy + control yogurt (S + YC) and soy + probiotic yogurt (S + YP),
respectively and for the prebiotic cohort were soy control (SC) and soy + resistant starch bread (S
+ RS), respectively. To assist with compliance, subjects with a preference for either yogurt or
bread were allocated accordingly; otherwise, allocation to the probiotic or prebiotic intervention
was random as was the order of the crossover.
For each test meal and daily during both 5-week dietary periods, all subjects consumed
250 mL soy milk (So Natural, UHT Calciforte, Taren Point, NSW, Australia) and 45 g soy cereal
(Specialty Cereals, Mt Kuring-gai, NSW, Australia). This provided a total of 38 mg daidzein and
68 mg genistein and 4.5 mg glycitein, with the majority of this provided by the cereal (29 mg
daidzein + 55 mg genistein + 4.5 mg glycitein). Sufficient quantities of each food were provided
to subjects at the beginning of each dietary period; soy milk was provided in 1 L cartons, from
which subjects were asked to measure and consume 250 mL daily and soy cereal was prepackaged as individual 45 g serves.
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For the probiotic intervention, subjects consumed 100 mL yogurt per day (Vaalia, Pauls
Dairy, Brisbane, Qld, Australia) either with (probiotic) or without (control) live bacterial cultures.
The probiotic yogurt contained 108 colony forming units (CFU)/100 g daily serve of each of
Lactobacillus GG, Lactobacillus acidophilus and Bifidobacterium bifidus. Both control and
probiotic yogurts were vanilla flavored with “low” fat (1.4%) content; there were no flavor or
texture differences between the two types and the containers were unmarked except for a
numerical code. Individual 100 mL serves of yogurt were provided fresh to subjects every 3
weeks and stored under refrigeration. For the prebiotic intervention, bread was baked using 70 %
resistant starch flour (Penford Australia Ltd, Sydney, NSW, Australia) by a local bakery (K & M
Bakery, Woonona, NSW, Australia) to provide approximately 4 g resistant starch per slice.
Bread was baked every 2 - 3 weeks and either delivered to subjects on the day of baking or frozen
in the clinic area for pick-up. Subjects consumed 4 - 5 slices of bread per day (to provide a total
of 16 - 20 g RS).
At the start of weeks 0, 5, 9 and 14, subjects attended the clinic at the University of
Wollongong on two consecutive days. On the first morning, a fasted blood sample was taken, a
food frequency questionnaire was administered, and subjects commenced a 24 h urine collection.
Next, a test meal consisting of 250 mL soy milk and 45 g soy cereal was eaten as breakfast in the
clinic. Subjects were instructed not to consume any other soy foods, probiotics or prebiotics for
48 h post-meal. Blood was again collected 8 and 24 h after the test meal and a second 24 h urine
sample was collected between 24 and 48 h post-meal. Urine was collected in 2.5 L bottles
containing 1 g ascorbic acid; total volume of each 24 h collection was recorded and aliquots were
stored at -80oC until analysis. Blood was collected by a registered nurse in the clinic area into
EDTA tubes (Sarstedt) which were inverted and placed on ice until centrifuged at 4oC for 10 min
at 2100 g; plasma was harvested and stored at -80oC until analysis.
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Sample Analysis
Extraction of isoflavones from plasma and urine was based on published methods using
β-glucuronidase enzymatic extraction (21) with modifications to optimize the procedure for local
use (22) and measurement via HPLC with ECD (22). All reagents and standards were obtained
from Sigma-Aldrich (Castle Hill, NSW, Australia) and solvents used for extractions, standard
preparations and HPLC analysis were HPLC grade (Crown Scientific, Moorebank, NSW,
Australia). In these purified, extracted samples, isoflavones were separated on a reverse phase C18 column (SGE Wakosil II 18RS), identified by HPLC (Shimadzu auto-injector) with an
isocratic mobile phase of 50 mM sodium acetate buffer pH 4.8 with acetic acid / methanol (45 /
55) and quantified by electrochemical detection at +750 mV (VT-03, Antec Leyden,
Zoeterwoude, The Netherlands). Mixed standards of genistein (Sigma, G6649), daidzein (Sigma,
D7802), equol (Sigma, 45405), O-desmethylangolensin (ODMA; Plantech, UK) at 4 different
concentrations (between 0.2 µM and 2 µM for plasma and between 0.2 µM and 4 µM for urine)
were included in each HPLC run at least in triplicate. Limits of quantification for plasma and
urine, respectively were 5 ng/mL and 1 µg/mL, for daidzein and genistein, 15 ng/mL and 2
µg/mL, for equol and 60 ng/mL and 6 µg/mL, for ODMA (22). Within-run coefficients of
variation for peak area of standards (% standard deviation/mean) were less than 5% for daidzein
and genistein, less than 10% for equol and less than 20% for ODMA. Recoveries were greater
than 70% and calculated values were not adjusted for recovery.
Ethics
Ethical approval for this study was granted by the University of Wollongong Human
Research Ethics Committee (Ethics Number 02/248) and all procedures complied with National
Health and Medical Research Council standards required in Australia. Written, informed consent
was obtained from all subjects prior to commencement of the study.
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Statistics
Initially, the normality of data sets was examined and outliers were identified (SPSS 11.0
and 11.5, SPSS Inc. Chicago, Illinois). ANOVA with repeated measures and Bonferroni posthoc analysis (SPSS 11.5, SPSS Inc. Chicago, Illinois) were used and reported with F values, df
(hypothesis df, error df) and p values. Student’s t-tests were 2-tailed (Microsoft Excel/SPSS
11.5, SPSS Inc. Chicago, Illinois). All values are reported as mean ± SEM.

RESULTS
Thirty-six subjects (15 females and 21 males) commenced the study, however 5 people
withdrew for personal reasons; consequently, 31 subjects (12 female and 19 male Australians of
Caucasian background) completed the study. The median subject age was 57.5 years (range 49 –
72 years) and subject age was not significantly different between the groups (F = 1.020, p =
0.399, one-way ANOVA with between groups analysis). Mean intake of daidzein and genistein
for each test soy meal and for the daily soy intake during dietary periods was 0.48 ± 0.01 and
0.84 ± 0.02 mg/kg body mass, respectively.
At week 0, females had significantly higher concentrations of plasma daidzein than males,
but there was no gender difference in plasma genistein (F = 8.386, p = 0.007 and F = 2.859, p =
0.102, respectively; one-way ANOVA with repeated measures and between groups analysis).
There were no differences between males and females for week 0 urinary excretion of either
daidzein or genistein (F = 1.555, p = 0.223 and F <0.0001, p = 0.992 respectively, one-way
ANOVA with repeated measures and between groups analysis). There was no significant order
effect for either dietary intervention and therefore, the two groups of each cohort were combined
for all analyses. In week 0 of each dietary period, plasma daidzein and genistein were still
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significantly elevated 24 h after the test soy meal compared with 0 h, as expected. The 0 h
plasma concentrations of daidzein and genistein were significantly increased after all four soy
dietary periods, independent of treatment.
In the probiotic cohort, S + YP did not affect plasma daidzein or genistein concentrations
significantly differently compared with S + YC (F1,15 = 0.416, p = 0.528 and F1,15 = 0.813, p =
0.382, respectively, three-way ANOVA with repeated measures; Figure 2, Table 1); however,
there was a greater increase in 0 h plasma daidzein concentration after probiotic treatment
compared with control, though this was not significant (F1,15 = 1.897, p = 0.189, two-way
ANOVA with repeated measures). After probiotic treatment, the plasma concentrations of
daidzein and genistein at 0 h of week 5 were higher than those at 24 h of week 0; this was
significant for genistein and almost so for daidzein (p = 0.043 and p = 0.058, respectively,
Student’s paired t-tests). In the prebiotic cohort, there were also no significant differences
between S + RS and SC for plasma concentrations of either daidzein or genistein (F1,15 = 0.416, p
= 0.528 and F1,15 = 0.813, p = 0.382, respectively, three-way ANOVA with repeated measures;
Figure 3, Table 2).
When the active treatments for the probiotic and prebiotic cohorts (S + YP and S + RS,
respectively) were compared, there were no significant differences between them for their effects
on plasma isoflavones (F = 0.440, p = 0.513 for daidzein and F = 0.623, p = 0.437 for genistein,
two-way ANOVA with repeated measures and between-groups analysis, Figure 4).
None of the four 5-week dietary treatments significantly affected urinary daidzein or
genistein concentrations and there were no significant differences between S + YC and S + YP
(daidzein: F1,15 = 0.013, p = 0.909; genistein: F1,15 = 0.499, p = 0.491) nor SC and S + RS
(daidzein: F1,13 = 0.537, p = 0.477; genistein: F1,13 = 3.287, p = 0.093, three way ANOVA with
repeated measures, Table 3).
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There was high inter-individual variability in the occurrence of equol and ODMA in
plasma and urine and subjects were classified into one of three subgroups based on distinct
differences between the pattern and frequency of occurrence of equol in their plasma or urine.
These subgroups were approximate tertiles: equol-positive (eql(+)) included 12 subjects who
consistently had equol in their plasma and/or urine, equol-occasional (eql(o)) included 10
subjects who had plasma or urinary equol in a single plasma or urine sample and equol-negative
(eql(-)) included 9 subjects who never had equol in their plasma or urine. There were no
significant differences between subjects in these subgroups for body mass, BMI or age at
baseline, nor in week 0 plasma or urinary concentrations of daidzein or genistein. None of the
treatments significantly affected the plasma or urinary concentrations of equol in either the eql(+)
or eql(o) subjects, nor did any of the treatments induce equol formation in eql(-) subjects.
Throughout the study, mean plasma daidzein and genistein tended to be lowest in eql(-)
subjects and highest in eql(+) subjects; however, variability was large and there were no
significant differences between the three subgroups (F = 1.113, p = 0.343 for daidzein and F =
2.228, p = 0.127 for genistein, two-way ANOVA with repeated measures and between groups
analysis, Figure 5). There were no significant differences or trends between the subgroups for
urinary excretion of daidzein or genistein (F = 0.157, p = 0.856 and F = 0.315, p = 0.732
respectively, two-way ANOVA with repeated measures and between groups analysis).
DISCUSSION
In the current study, neither the addition of probiotic bacteria nor a prebiotic ingredient to
a soy diet significantly affected isoflavone absorption or metabolism. This was in contrast to our
hypothesis that intake probiotic and prebiotic intake, by virtue of their individual effects on gut
microflora and enzyme activity necessary for isoflavone absorption and metabolism could
potentially increase isoflavone bioavailability.
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The lack of any significant effects of probiotic intake may indicate either that the levels of
probiotic bacteria provided were insufficient to affect gut microfloral balance or that any gut
microfloral changes that did occur did not further affect isoflavone absorption. Our probiotic
yogurt was purported by the supplier to contain 108 colony forming units (CFU)/100 g of each of
Lactobacillus acidophilus, Bifidobacterium bifidus and Lactobacillus GG. This level of bacterial
activity should be sufficient to affect gut microfloral balance as probiotic effects in the
gastrointestinal tract have been reported with minimum daily doses of between 108 and 109 viable
cells (13,23-25). Oral administration of these probiotic bacteria results in increased populations
in the human gastrointestinal tract and faeces (25-28, 31-35) and increased fecal β-glucosidase
activity (36). Such increases in lactobacilli and bifidobacteria intake and concomitant
enhancement in intestinal β-glucosidase activity would be expected to enhance initial hydrolysis
and absorption of dietary isoflavone glycosides. However, a recent randomized, crossover trial
with 40 postmenopausal women also reported no effect of bacterial supplementation (109 CFU
Lactobacillus acidophilus and Bifidobacterium longum) with daily intake of soy protein isolate
plus 44 mg isoflavones on plasma isoflavone concentrations after 6 weeks (37). Together with
our study, this suggests that soy isoflavone bioavailability is not affected by concurrent probiotic
intake as either a supplement (37) or a dietary component (current study).
The absence of any significant changes in isoflavone bioavailability with resistant starch
intake again suggests either a lack of effect on the gut microflora or that such effects had no
impact on isoflavone absorption and metabolism. Although we did not determine gastrointestinal
microbial activity in the current study, prebiotic effects have been reported after 2 – 4 weeks of
daily RS intake of between 15 and 55 g (38-42), thus it is likely the RS intake in the current study
had a similar effect. Resistant starch specifically stimulates the growth of bifidobacteria in the
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colon (15,43) and increases caecal lactobacilli and bifidobacteria levels in human flora-associated
rats (16). Bifidobacteria can hydrolyze daidzin and genistin from soy milk to their respective
aglycones (44) and metabolize daidzein in human faecal samples (45,46) and these effects have
been attributed to its β-glucosidase activity (36,44). Both bifidobacteria and lactobacilli possess
high β-glucosidase activity (16,36) and are also the dominant native microflora in the duodenum
and jejunum where most of the initial isoflavone hydrolysis is likely to occur (9). Interestingly,
Lactobacillus acidophilus and Bifidobacterium bifidus do not increase β-glucuronidase activity in
the human gastrointestinal tract (29,36,47,48), thus the lack of prebiotic or probiotic observed
here suggest that β-glucuronidase activity may be more important than β-glucosidase activity in
isoflavone bioavailability.
Although subjects were instructed to maintain their normal diets, many foods contain
prebiotics and contribute to the microbial activity of the gastrointestinal tract. With no measure
of this in the current study, we are unable to attribute the results of resistant starch intake to a
specific prebiotic effect. Fructooligosaccharide (FOS), a prebiotic similar to RS, also increases
fecal bifidobacteria (49) and affects gut microflora balance (50) and was reported to prolong the
clearance of daidzein and genistein and increase their bioavailability in rats (51). We previously
found altered isoflavone metabolism with resistant starch intake, including enhanced metabolism
of daidzein to equol (Larkin et al, manuscript submitted). In the current study, the mean plasma
isoflavone concentrations 24 h post-meal were highest after 5 weeks of soy and resistant starch
intake and although not significant, this finding is interesting to note as it also suggests prolonged
plasma isoflavone clearance following a single soy meal. Overall, there may be a potential
prebiotic effect on isoflavone bioavailability; however, the relevance of dietary-induced changes
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in gastrointestinal microfloral activity to isoflavone bioavailability is rather poorly understood
and requires further investigation.
In the current study, 12 subjects (39%) consistently metabolized daidzein to equol, a
similar proportion to that reported in other soy studies (52-54). All four soy dietary periods
increased plasma equol levels in the initial (0 h) measurement, implying that 5 weeks of daily soy
intake (with or without a probiotic or prebiotic) was sufficient to increase plasma equol in those
who are predisposed to this conversion. However, the concurrent consumption of either a
probiotic or prebiotic with soy did not affect equol concentration or the number of people who
produced equol, nor did it induce equol production. Lactobacilli and bifidobacteria have been
identified as playing a role in the metabolism of daidzein to equol (17,44,55) (56) and the short
chain fatty acid products of resistant starch intestinal fermentation (42,57,58) increase daidzein
conversion to equol in faeces (17); however, increased intake of either these probiotic bacteria or
resistant starch did not affect equol production in the current study. Previous studies also report
no effect of either probiotic (37) or dietary fibre (52) supplementation with soy consumption on
equol-producing capacity, suggesting genetics may contribute to this ability (59). In the current
study, equol occurrence varied greatly between individuals and within subjects on different
occasions, as has been previously reported (60-62). This large variability, combined with a small
numbers of subjects, was a clear limitation. There was a pattern however, although not
significant, for subjects who produced equol to have higher plasma concentrations of daidzein
and genistein, suggesting that a high level of initial isoflavone absorption may be a determining
factor for equol production, as previously proposed (44).
CONCLUSIONS
Concurrent consumption of soy with either a probiotic or prebiotic dietary component did
not significantly alter plasma or urinary daidzein or genistein concentrations or equol-producing
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ability of the subjects in this study. However, our results suggest minor effects on soy isoflavone
bioavailability with probiotic or prebiotic intake. Further investigation, including exploration
into the roles of specific gut microflora, will assist in the establishment of dietary conditions to
enhance isoflavone bioavailability and equol production, particularly if the latter is conclusively
associated with increased health benefits.

16

REFERENCES

1. Winter, J. & Bokkenheuser, V. Bacterial metabolism of natural and synthetic sex hormones
undergoing enterohepatic circulation. J Steroid Biochem1987; 27: 1145-1149.
2. Rowland, I., Wiseman, H., Sanders, T., Adlercreutz, H. & Bowey, E. Metabolism of
oestrogens and phytoestrogens: role of the gut microflora. Biochem Soc Trans 1999; 27: 304308.
3. Adlercreutz, H. Evolution, nutrition,intestinal microflora, and prevention of cancer: A
hypothesis. Proc Soc Expl Biol Med 1998; 217: 241-246.
4. Xu, X., Wang, H., Murphy, P. & Hendrich, S. Neither background diet nor type of soy food
affects short-term isoflavone bioavailability in women. J Nutr 2000;130: 798-801.
5. Izumi, T., Piskula, M., Osawa, S., Obata, A., Tobe, K., Saito, M., Kataoka, S., Kubota, Y. &
Kikuchi, M. Soy isoflavone aglycones are absorbed faster and in higher amounts than their
glucosides in humans. J. Nutr 2000;130: 1695-1699.
6. Setchell, K., Brown, N., Desai, P., Zimmer-Nechemias, L., Wolfe, B., Brashear, W., Kirschner,
A., Cassidy, A. & Heubi, J. Bioavailability of pure isoflavones in healthy humans and analysis
of commercial soy isoflavone supplements. J Nut 2001; 131: 1362S-1375S.
7. Steer, T., Johnson, I., Gee, J. & Gibson, G. Metabolism of the soyabean isoflavone glycoside
genistin in vitro by human gut bacteria and the effect of prebiotics. Brit J Nutr 2003; 90: 635642.
8. Xu, X., Harris, K., Wang, H. & Murphy, P. Bioavailability of soybean isoflavones depends
upon gut microflora in women. J Nutr 1995;125: 2307-2315.

17
9. Turner, N., Thomson, B. & Shaw, I. Bioactive Isoflavones in functional foods: The importance
of gut microflora on bioavailability. Nutr Rev 2003; 61: 204 - 213.
10. Gibson, G. Dietary Modulation of the human gut microflora using prebiotics. Brit J Nutr 1998;
80: S209-S212.
11. O'Sullivan, D. Screening of intestinal microflora for effective probiotic bacteria. J of Agri Food
Chem2001; 49: 1751-1760.
12. Cummings, J., Roberfroid, M., Andersson, H., Barth, C., Ferro-Luzzi, A., Ghoos, Y., et al. A.
A new look at dietary carbohydrate: chemistry, physiology and health. Euro J Clin Nutr 1997;
51: 417-423.
13. Gomes, A. & Malcata, F. Bifidobacterium spp. and Lactobacillus acidophilus: biological,
biochemical, technological and therapeutical properties relevant for use as probiotics. Trends
Food Sci Tech 1999; 10: 139-157.
14. Gibson, G. Dietary modulation of the human gut microflora using the prebiotics pligofructose
and inulin. J Nutr 1999; 129: 1438S-1441S.
15. Brown, I., Wang, X. & Conway, P. Sticky and selective starches. Microbiology Australia 1999;
18-19.
16. Silvi, S., Cresci, R. & Rowland, I. Resistant starch modifies gut microflora and microbial
metabolism in human flora-associated rats inoculated with faeces from Italian and UK donors.
J Appl Microbiol 1999; 86: 521-530.
17. Decroos, K., Vanhemmens, S., Cattoir, S., Boon, N. & Verstraete, W. Isolation and
characterisation of an equol-producing mixed microbial culture from a human faecal sample
and its activity under gastrointestinal conditions. Arch Microbio 2005; 183: 45 - 55.
18. Arora, A., Nair, M. & Strasburg, G. Antioxidant activites of isoflavones and their biological
metabolites in a liposomal system. Arch Biochem Biophys 1998;356: 133-141.

18
19. Mitchell, J., Gardner, P., McPhail, D., Morrice, P., Collins, A. & Duthie, G. Antioxidant
efficacy of phytoestrogens in chemical and biological model systems. Arch Biochem
Biophys1998; 360: 142-148.
20. Atkinson, C., Frankenfeld, C. & Lampe, J. Gut bacterial metabolism of the soy isoflavone
daidzein: exploring the relevance to human health. Expl Biol Med 2005; 230: 155-170.
21. Gamache, P. & Acworth, I. Analysis of phytoestrogens and polyphenols in plasma, tissue, and
urine using HPLC with coulometric array detection. Proceed Soc Expl Biol Med 1998; 217:
274-280.
22. Larkin, T. Soy Isoflavone bioavailability - effects of probiotic and prebiotic consumption and
oil supplementation. 2005; PhD thesis Univ of Wollongong.
23. Shimakawa, Y., Matsubara, S., Yuki, N., Ikeda, M. & Ishikawa, F. Evaluation of
Bifidobacterium breve strain Yakult-fermented soymilk as a probiotic food. Intl J Food
Microbio 2003; 81: 131-136.
24. Shin, H., Lee, J., Pestka, J. & Ustunol, Z. Viability of bifidobacteria in commercial dairy
products during refrigerated storage. J Food Protect 2000; 63: 327 - 331.
25. Chen, R., Wu, J., Lee, S., Huang, A. & Wu, H. (1999) Increase of intestinal bifidobacterium
and suppression of coliform bacteria with short-term yogurt ingestion. J Dairy Sci 2000; 82:
2308-2314.
26. Cummings, J. & Macfarlane, G. Role of intestinal bacteria in nutrient metabolism. JPEN, J
Parenteral Ent Nutr 1997; 21: 357-365.
27. Dunne, C., O'Mahony, L., Murphy, L., Thornton, G., Morrissey, D., O'Halloran, S., et al. In
vitro selection criteria for probiotic bacteria of human origin: correlation with in vivo findings.
Am J Clin Nutr 2001; 73: 386S-392S.

19
28. Rolfe, R. The role of probiotic cultures in the control of gastrointestinal health. J Nutr 2000;
130: 396S-402S.
29. Gorbach, S. & Goldin, B. Nutrition and the gastrointestinal microflora. Nutr Rev1992; 50: 378
- 381.
30. Bezkorovainy, A. Probiotics: determinants of survival and growth in the gut. Am J Clin Nutr
2001; 73: 399S - 405S.
31. Crittenden, R., Morris, L., Harvey, M., Tran, L., Mitchell, H. & Playne, M. Selection of a
Bifidobacterium strain to complement resistant starch in a synbiotic yoghurt. J Appl Microbio
2001;90: 268-278.
32. Hove, H., Norgaard, H. & Mortensen, P. B. Review lactic acid bacteria and the human
gastrointestinal tract. Euro J Clin Nutr 1999; 53: 339-350.
33. Kailasapathy, K., Chin & Jacobasch, G. Survival and therapeutic potential of probiotic
organisms with reference to Lactobacillus acidophilus and Bifidobacterium spp. Immunol Cell
Biol 2000; 78: 80-88.
34. Bartram, H., Scheppach, W., Gerlach, S. & Ruckdeschel, G. Does yogurt enriched with
Bifidobacterium longum affect microbiology and fecal metabolites in healthy subjects? Am J
Clin Nutr 1994; 59: 428
35. Guerin-Danan, C., Chabanet, C., Pedone, C., Popot, F., Vaissade, P., Bouley, C., et al. Milk
fermented with yogurt cultures and Lactobacillus casei compared with yogurt and gelled milk:
influence on intestinal microflora in healthy infants. Am J Clin Nutr 1998; 67: 111-117.
36. Marteau, P., Pochart, P., Flourie, B., Pellier, P., Santos, L., Desjeux, J. & Rambaud, J. Effect of
chronic ingestion of a fermented dairy product containing Lactobacillus acidophilus and
Bifidobacterium bifidum on metabolic activities of the colonic flora in humans. Am J Clin Nutr
1990; 52: 685 - 688.

20
37. Nettleton, J., Greany, K., Thomas, W., Wangen, K., Adlercreutz, H. & Kurzer, M. Plasma
phytoestrogens are not altered by probiotic consumption in postmenopausal women with and
without a history of breast cancer. J Nutr 2004;134: 1998 - 2003.
38. Hylla, S., Gostner, A., Dusel, G., Anger, H., Bartram, H., Christl, S., Kasper, H. & Scheppach,
W. Effects of resistant starch on the colon in healthy volunteers: possible implications for
cancer prevention. Am J Clin Nutr 1998;67: 136-142.
39. Cummings, J., Beatty, E., Kingman, S., Bingham, S. & Englyst, H. Digestion and
physiological properties of resistant starch in the human large bowel. Br J Nutr 1996; 75: 733747.
40. Phillips, J., Muir, J., Burkett, A., Lu, Z., Jones, G., O'Dea, K. & Young, G. Effect of resistant
starch on fecal bulk and fermentation-dependent events in humans. Am J Clin Nutr 1995; 62:
121-130.
41. Schwiertz, A., Lehmann, U., Jacobasch, G. & Blaut, M. Influence of resistant starch on the
SCFA production and cell counts of butyrate-pdorucing Eubacterium spp. in the human
intestine. J Appl Microbiol 2002; 93: 157-162.
42. Topping, D. & Clifton, P. Short-chain fatty acids and human colonic function: Roles of
resistant starch and nonstarch polysaccharides. Physiol Rev 2001; 81: 1031-1064.
43. Wang, X., Brown, I., Khaled, D., Mahoney, M., Evans, A. & Conway, P. Manipulation of
colonic bacteria and volatile fatty acid production by dietary high amylose maize (amolymaize)
starch granules. J Appl Microbiol 2002; 93: 390-397.
44. Tsangalis, D., Ashton, J., McGill, A. & Shah, N. Enzymic transformation of isoflavone
phytoestrogens in soymilk by B-glucosidase-producing bifidobacteria. J Food Sci2002; 67:
3104 - 3113.

21
45. Chang, Y. & Nair, M. Metabolism of daidzein and genistein by intestinal bacteria. J Nat Prod
1995; 58: 1892-1896.
46. Kim, D., Yu, K., Bae, E. & Han, M. Metabolism of puerarin and daidzein by human intestinal
bacteria and their relation to in vitro Cytotoxicity. Biol Pharm Bull 1998; 21: 628-630.
47. Ling, W., Korpela, R., Mykkanen, H., Salminen, S. & Hanninen, O. Lactobacillus strain GG
supplementation decreases colonic hydrolytic and reductive enzyme activities in healthy
female adults. J Nutr1994, 124: 18 - 23.
48. Rowland, I., Mallett, A. & Wise, A. The effect of diet on the mammalian gut flora and its
metabolic activities. CRC Crit Rev Toxicol 1985; 16: 31 - 103.
49. Bouhnik, Y., Vahedi, K., Achour, L., Attar, A., Salfati, J., Pochart, P., et al., J. Short-chain
fructo-oligosacchharide administration dose-dependently increases fecal Bifidobacteria in
healthy humans. J Nutr 1999; 129: 113-116.
50. Cummings, J., Macfarlane, G. & Englyst, H. Prebiotic digestion and fermentation. Am J Clin
Nutr 2001; 73: 415S-420S.
51. Uehara, M., Ohta, A., Sakai, K., Suzuki, K., Watanabe, S. & Adlercreutz, H. Dietary
fructooligosaccharides modify intestinal bioavailability of a single dose of genistein and
daidzein and affect their urinary excretion and kinetics in blood of rats. J Nutr 2001; 131: 787795.
52. Lampe, J., Skor, H., Li, S., Wahala, K., Howald, W. & Chen, C. Wheat bran and soy protein
feeding do not alter urinary excretion of the isoflavan equol in premenopausal women. J Nutr
2001; 131: 740-744.
53. Lampe, J., Karr, S., Hutchins, A. & Slavin, J. Urinary equol excretion with a soy challenge:
influence of habitual diet. Proceed Soc Expt Biol Med 1998; 217: 335-339.

22
54. Slavin, J., Karr, S., Hutchins, A. & Lampe, J. Influence of soybean processing, habitual diet,
and soy dose on urinary isoflavonoid excretion. Am J Clin Nutr 1998; 68: 1492S-1495S.
55. Ueno, T. & Uchiyama, S. Identification of the specific intestinal bacteria capable of
metabolising soy isoflavone to equol. Ann Nutr Metab 2001; 45: 114.
56. Atkinson, C., Berman, S., Humbert, O. & Lampe, J. In vitro incubation of human feces with
daidzein and antibiotics suggests interindividual differences in the bacteria responsible for
equol production. J Nutr 2004; 134: 596 - 599.
57. Rowland, I. Optimal nutrition: fibre and phytochemicals. Proceed Nutr Soc 1999; 58: 415-419.
58. Brown, I., Wang, X., Topping, D., Playne, M. & Conway, P. High amylose maize starch as a
versatile prebiotic for use with probiotic bacteria. Food Australia 1998; 50: 602-609.
59. Akaza, H., Miyanaga, N., Takashima, N., Naito, S., Hirao, Y., Tsukamoto, et al., A.
Comparisons of percent equol producers between prostate cancer patients and controls: Casecontrolled studies of isoflavones in Japanese, Korean and American residents. Jap J Clin
Oncol2004; 34: 86 - 89.
60. Zhang, Y., Wang, G., Song, T., Murphy, P. & Hendrich, S. Urinary disposition of the soybean
isoflavones daidzein, genistein and glycitein differs among humans with moderate fecal
isoflavone degradation activity. J Nutr 1999; 129: 957-962.
61. Hendrich, S., Wang, G., Xu, X., Tew, B., Wang, H. & Murphy, P. Human bioavailability of
soy bean isoflavones: Influences of diet, dose, time, and gut microflora. In: Functional Foods
for Disease Prevention (Shibamoto, T., Terao, J. & Osawa, T., eds.), pp. 150 - 156. 1998; ACS,
Washington, D.C.
62. Rafii, F., Davis, C., Park, M., Heinze, T. & Beger, R. Variations in metabolism of the soy
isoflavonoid daidzein by human intestinal microfloras from different individuals. Arch
Microbiol 2003; 180: 11 - 16.

23
FIGURE LEGENDS

Figure 1. Study Design. There were 2 groups for each cohort: probiotic (Pro-1 and Pro-2) and
prebiotic (Pre-1 and Pre-2); these followed complementary orders of dietary treatments. S+YC =
soy plus control yogurt; S+YP = soy plus probiotic yogurt; SC = soy control, S+RS = soy plus
resistant starch. Soy test meals were given at the beginning and end of each 5 week dietary
period.

Figure 2. Probiotic cohort - Effect of 5 weeks soy + control yogurt (S + YC) and 5 weeks soy +
probiotic yogurt (S + YP) on mean plasma daidzein and genistein concentrations. Mean ± SEM,
n = 17. *Significant p<0.017, post-hoc Student’s paired t-tests with Bonferroni adjustment.

Figure 3. Prebiotic cohort - Effect of 5 weeks soy control (SC) and 5 weeks soy + resistant starch
(S + RS) on mean plasma daidzein and genistein concentrations. Mean ± SEM, n = 14.
*Significant p<0.017, post-hoc Student’s paired t-tests with Bonferroni adjustment.

Figure 4. Change in plasma daidzein and genistein after 5 weeks of soy + probiotic yogurt (S +
YP) and 5 weeks of soy + resistant starch (S + RS).

Figure 5. Mean plasma daidzein and genistein concentrations throughout the study based on
equol-producing ability of subjects as determined by HPLC quantification of samples: eql (+)
subjects consistently had plasma and/or urinary equol, n = 12; eql (o) subjects had equol in a
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single plasma or urine sample, n = 10; eql (-) subjects had no observable plasma or urinary equol,
n = 9.
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Table 1. Mean plasma daidzein and genistein concentrations after each test soy meal for probiotic cohort

time†

Plasma sample *
Week

0h

8h
a

daidzein

S + YC

(ng/mL)

0
5

S + YP

0
5

genistein

S + YC

(ng/mL)

0
5

S + YP

0

1.9 ± 1.5
(0 – 23.6)
a
45.0 ± 16.8
(0 – 260)
a
3.0 ± 2.2
(0 – 34.2)
d
66.2 ± 17.8
(4.1 – 237)
a
3.5 ± 2.4
(0 – 31.9)
a
158 ± 38.8
(0 – 514)
a
2.8 ± 1.7
(0 – 20.3)

24 h
b

169 ± 19.3
(65.3 – 333)
b
193 ± 22.7
(50.4 – 350)
b
176 ± 20.4
(33.0 – 374)
e
154 ± 20.8
(12.2 – 364)
b
412 ± 53.5
(129 – 1009)
b
472 ± 57.8
(149 – 1019)
b
412 ± 64.7
(67.2 – 972)

week‡

F 2,14

p

36.615

<0.0001

week x time‡

F 1,15

p

F 2,14

p

9.905

0.007

5.393

0.018

5.636

0.031

5.646

0.016

8.205

0.012

5.641

0.061

c

38.3 ± 8.5
(0 – 156)
a
41.2 ± 12.0
(4.1 – 190)
c
30.3 ± 5.7
(0 – 78.5)
d
34.5 ± 5.9
(0 – 97.0)
c
134 ± 18.0
(23.0 – 281)
a
175 ± 34.4
(32.5 – 487)
c
116 ± 17.8
(14.8 – 295)

35.195

<0.0001

33.805

<0.0001

17.035

<0.0001

34.022

<0.0001

23.725

<0.0001

21.271

<0.0001

13.810
8.199
0.002
0.004
d
e
d
201 ± 45.5
401 ± 49.4
144 ± 24.9
16.387
<0.0001
5
(46.1 – 682)
(38.8 – 701)
(42.4 – 454)
* Values in a row with different superscript letters are significantly different. a, b, c - p < 0.002, d – p < 0.05, Bonferroni post-hoc analysis.
†One-way ANOVA with repeated measures.
‡Two-way ANOVA with repeated measures.

Table 2. Mean plasma daidzein and genistein concentrations after each test soy meal for prebiotic cohort

time†

Plasma sample *
Week

0h

8h
a

24 h
b

F 2,11

week‡
p

F 1,12

0

p

F 2,11

p

0.001

5.401

0.023

0.039

4.569

0.036

0.000

4.900

0.030

0.003

4.484

0.038

c

2.2 ± 1.2
158 ± 20.4
36.0 ± 7.6
25.893 <0.0001
(0 – 13.1)
(72.9 – 303)
(9.1 – 104)
18.710
SC
a
b
a
43.1 ± 12.9
187 ± 21.7
38.7 ± 7.9
(ng/mL)
47.316 <0.0001
5
(0 – 162)
(57.1 – 346)
(6.1 – 104)
a
b
c
4.9 ± 3.9
170 ± 19.0
37.5 ± 8.1
39.946 <0.0001
0
(0 – 54.7)
(68.3 – 324)
(8.4 – 93.4)
5.355
S + RS
a
b
a
45.7 ± 10.4
182 ± 21.1
56.3 ± 15.1
44.655 <0.0001
5
(0 – 133)
(66.0 – 357) (12.3 – 198)
a
b
c
1.7 ± 1.2
388 ± 49.2
113 ± 10.6
49.971 <0.0001
0
genistein
(0 – 14.7)
(167 – 744)
(61.8 – 184)
45.825
SC
a
b
a
197 ± 47.4
479 ± 51.6
167 ± 24.0
(ng/mL)
51.883 <0.0001
5
(58.3 – 598)
(139 – 800)
(66.6 – 365)
a
b
c
2.2 ± 1.7
403 ± 56.3
143 ± 33.7
52.852 <0.0001
0
(0 – 24.1)
(129 – 938)
(44.6 – 486)
14.044
S + RS
a
b
a
153 ± 27.7
516 ± 69.1
215 ± 60.2
30.018 <0.0001
5
(0 – 355)
(140 – 1010) (67.5 – 876)
* Values in a row with different superscript letters are significantly different. p < 0.02, Bonferroni post-hoc analysis.
†
One-way ANOVA with repeated measures.
‡
Two-way ANOVA with repeated measures.

daidzein

week x time‡

Table 3. Urinary daidzein and genistein concentrations – A. probiotic cohort; B. prebiotic cohort.
0 – 24 h*

24 - 48 h

0 – 48 h

0

12.0 ± 1.0
(5.8 – 21.7)
13.2 ± 1.3
(3.2 – 20.4)
12.0 ± 1.3
(3.8 – 20.1)
14.2 ± 1.6
(4.0 – 27.8)
6.1 ± 0.68
(2.1 – 11.8)
7.6 ± 1.0
(1.5 – 17.1)
5.8 ± 0.79
(1.3 – 10.9)
7.4 ± 0.97
(0.81 – 16.9)
10.4 ± 2.4
(2.8 – 18.3)
13.5 ± 2.3
(0 – 34.8)
10.3 ± 1.4
(3.3 – 21.3)
12.4 ± 2.1
(4.2 – 39.0)
5.7 ± 0.87
(1.4 – 13.6)
7.2 ± 1.3
(0 – 16.7)
6.7 ± 1.4
(1.5 – 17.4)

5.0 ± 1.4
(0.79 – 21.6)
4.6 ± 1.4
(0.47 – 23.1)
4.1 ± 1.1
(0.68 – 16.8)
4.8 ± 0.91
(1.6 – 15.5)
2.4 ± 0.80
(0 – 11.8)
3.1 ± 1.5
(0 – 25.3)
2.0 ± 0.91
(0 – 15.1)
2.5 ± 0.62
(0 – 7.4)
2.4 ± 0.45
(0.57 – 18.3)
4.9 ± 1.6
(0.69 – 23.0)
4.2 ± 1.1
(0.80 – 13.9)
6.5 ± 2.1
(1.2 – 25.7)
0.81 ± 0.14
(0.20 – 2.2)
1.8 ± 0.52
(0 – 6.2)
2.6 ± 0.82
(0 – 9.1)

17.0 ± 1.9
(10.1 – 37.6)
17.8 ± 2.1
(4.0 – 38.1)
16.1 ± 2.0
(5.8 – 30.4)
19.0 ± 2.1
(5.6 – 34.5)
8.5 ± 1.1
(2.5 – 16.0)
10.8 ± 2.2
(2.7 – 38.3)
7.7 ± 1.3
(1.6 – 20.6)
9.9 ± 1.5
(0.81 – 23.9)
12.7 ± 1.2
(3.3 – 21.4)
18.1 ± 3.2
(2.0 – 57.9)
14.2 ± 2.2
(4.3 – 28.9)
18.5 ± 3.6
(5.9 – 61.3)
6.4 ± 0.97
(1.6 – 15.8)
8.8 ± 1.6
(0.60 – 22.9)
9.1 ± 2.0
(1.5 – 25.2)

5

7.0 ± 0.84
(2.3 – 13.4)

2.8 ± 0.86
(0.30 – 10.5)

9.7 ± 1.5
(2.6 – 21.9)

Wk
A.

daidzein

S + YC

(mg)

0
5

S + YP

0
5

genistein

S + YC

(mg)

0
5

S + YP

0
5

B.

daidzein

SC

(mg)

0
5

S + RS

0
5

genistein

SC

(mg)

0
5

S + RS

F1,15†

p

0.128

0.726

p‡
0.001
<0.0001

1.576

0.229

<0.0001
<0.0001

1.242

0.283

0.003
0.006

2.424

0.140

0.005
<0.0001

2.650

0.128

<0.0001
0.001

0.689

0.421

<0.0001
0.013

3.781

0.074

<0.0001
0.001

0.036

0.853

0.001
<0.0001

*Mean ± SEM (range in parentheses)
†

Two way ANOVA with repeated measures for effect of dietary period on 0 – 24 h and 24 – 48 h urinary isoflavone excretion.

Table 4. Plasma and urinary equol concentrations for equol-positive subjects (n = 12).

Cohort
Probiotic

Treatment
S + YC
S + YP

Prebiotic

SC
S + RS

Wk
0
5
0
5
0
5
0
5

Plasma equol (ng/mL)
0h
8h
24 h
0
49.7 ± 17.7
26.4 ± 19.6
69.9 ± 45.0
11.2 ± 11.2
37.2 ± 10.5
6.7 ± 4.5
28.2 ± 16.2

37.5 ± 25.5
53.8 ± 32.6
49.3 ± 30.4
60.1 ± 34.8
43.6 ± 20.8
30.4 ± 16.8
29.5 ± 17.0
44.0 ± 18.6

46.1 ± 26.9
31.7 ± 18.8
39.7 ± 13.5
64.0 ± 31.2
31.1 ± 13.3
46.9 ± 11.8
29.8 ± 21.5
29.6 ± 10.6

Urinary equol (mg)
0 – 24 h 24 – 48 h
2.4 ± 2.4
1.2 ± 1.1
1.1 ± 0.47
1.9 ± 1.5
0.83 ± 0.71
1.2 ± 0.68
0.44 ± 0.43
0.85 ± 0.85

1.1 ± 1.0
1.3 ± 1.0
0.51 ± 0.40
2.0 ± 1.2
0.28 ± 0.15
0.35 ± 0.14
0.80 ± 0.65
0.95 ± 0.54

